Concepts (243)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Suicidal Ideation | 5 | 2022 | 96 | 1.670 |
Why?
|
| Suicide, Attempted | 5 | 2022 | 92 | 1.500 |
Why?
|
| Suicide | 4 | 2022 | 116 | 1.470 |
Why?
|
| Firearms | 6 | 2022 | 31 | 1.450 |
Why?
|
| Self-Injurious Behavior | 4 | 2022 | 44 | 1.280 |
Why?
|
| Depression | 8 | 2020 | 486 | 0.860 |
Why?
|
| Mindfulness | 4 | 2020 | 30 | 0.800 |
Why?
|
| Patient Care Management | 1 | 2022 | 25 | 0.750 |
Why?
|
| Substance-Related Disorders | 4 | 2021 | 425 | 0.720 |
Why?
|
| Wounds, Gunshot | 2 | 2022 | 18 | 0.720 |
Why?
|
| Internet | 5 | 2022 | 212 | 0.710 |
Why?
|
| Humans | 38 | 2022 | 17314 | 0.630 |
Why?
|
| Benzodiazepines | 1 | 2019 | 28 | 0.630 |
Why?
|
| Sexual and Gender Minorities | 2 | 2017 | 31 | 0.630 |
Why?
|
| Sleep Wake Disorders | 1 | 2019 | 34 | 0.620 |
Why?
|
| Anxiety Disorders | 1 | 2019 | 92 | 0.610 |
Why?
|
| Telemedicine | 4 | 2022 | 181 | 0.600 |
Why?
|
| Aging | 2 | 2017 | 160 | 0.590 |
Why?
|
| Mental Disorders | 2 | 2022 | 274 | 0.590 |
Why?
|
| Guideline Adherence | 1 | 2019 | 149 | 0.580 |
Why?
|
| Myelin Basic Protein | 4 | 2006 | 5 | 0.580 |
Why?
|
| Primary Health Care | 3 | 2021 | 726 | 0.580 |
Why?
|
| Adult | 18 | 2022 | 7500 | 0.540 |
Why?
|
| Homosexuality | 1 | 2016 | 5 | 0.520 |
Why?
|
| Psychotherapy, Group | 1 | 2014 | 20 | 0.430 |
Why?
|
| Male | 21 | 2022 | 9804 | 0.430 |
Why?
|
| Female | 25 | 2022 | 12396 | 0.420 |
Why?
|
| Middle Aged | 19 | 2022 | 7836 | 0.400 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2006 | 2 | 0.390 |
Why?
|
| International Classification of Diseases | 2 | 2022 | 86 | 0.350 |
Why?
|
| Qualitative Research | 5 | 2022 | 260 | 0.310 |
Why?
|
| Lipid Metabolism | 2 | 2000 | 13 | 0.300 |
Why?
|
| Behavior Therapy | 2 | 2022 | 126 | 0.290 |
Why?
|
| Colonic Neoplasms | 2 | 2019 | 163 | 0.280 |
Why?
|
| Membrane Lipids | 1 | 2006 | 1 | 0.260 |
Why?
|
| Oligodendroglia | 1 | 2006 | 1 | 0.260 |
Why?
|
| Adolescent | 5 | 2022 | 3538 | 0.250 |
Why?
|
| Delivery of Health Care | 3 | 2016 | 390 | 0.220 |
Why?
|
| Aged | 11 | 2022 | 6084 | 0.220 |
Why?
|
| Patient Care | 2 | 2022 | 29 | 0.220 |
Why?
|
| Colorado | 3 | 2020 | 164 | 0.210 |
Why?
|
| Depressive Disorder, Major | 2 | 2014 | 100 | 0.200 |
Why?
|
| Risk Factors | 6 | 2022 | 3258 | 0.200 |
Why?
|
| Patient Health Questionnaire | 2 | 2021 | 18 | 0.200 |
Why?
|
| Research Design | 2 | 2022 | 336 | 0.200 |
Why?
|
| Lipid Bilayers | 2 | 2001 | 2 | 0.200 |
Why?
|
| Case-Control Studies | 3 | 2022 | 1098 | 0.190 |
Why?
|
| Electronic Health Records | 4 | 2022 | 704 | 0.190 |
Why?
|
| Interviews as Topic | 4 | 2017 | 306 | 0.180 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2001 | 1 | 0.180 |
Why?
|
| Fatty Acids | 1 | 2001 | 8 | 0.180 |
Why?
|
| Evidence-Based Practice | 1 | 2021 | 55 | 0.180 |
Why?
|
| Schizophrenia | 2 | 2014 | 76 | 0.180 |
Why?
|
| Health Services | 1 | 2022 | 110 | 0.170 |
Why?
|
| Physicians | 1 | 2022 | 117 | 0.170 |
Why?
|
| Calmodulin | 1 | 2000 | 1 | 0.170 |
Why?
|
| Actins | 1 | 2000 | 3 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 312 | 0.160 |
Why?
|
| Child | 3 | 2022 | 2403 | 0.160 |
Why?
|
| Benchmarking | 1 | 2020 | 36 | 0.160 |
Why?
|
| Quality of Health Care | 2 | 2019 | 259 | 0.160 |
Why?
|
| Anxiety | 2 | 2020 | 154 | 0.160 |
Why?
|
| Psychotherapy | 1 | 2019 | 56 | 0.150 |
Why?
|
| Quality Assurance, Health Care | 3 | 2016 | 124 | 0.150 |
Why?
|
| Animals | 5 | 2006 | 280 | 0.150 |
Why?
|
| Sulfamethoxazole | 1 | 2018 | 1 | 0.150 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2018 | 3 | 0.150 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2018 | 6 | 0.150 |
Why?
|
| Trimethoprim | 1 | 2018 | 4 | 0.150 |
Why?
|
| United States | 4 | 2019 | 3866 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2018 | 243 | 0.140 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2018 | 66 | 0.140 |
Why?
|
| Depressive Disorder | 1 | 2019 | 185 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 310 | 0.140 |
Why?
|
| Organizational Objectives | 1 | 2017 | 14 | 0.140 |
Why?
|
| Program Development | 1 | 2017 | 63 | 0.130 |
Why?
|
| Ageism | 1 | 2016 | 2 | 0.130 |
Why?
|
| Community-Based Participatory Research | 1 | 2017 | 46 | 0.130 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 245 | 0.130 |
Why?
|
| Independent Living | 1 | 2016 | 24 | 0.130 |
Why?
|
| Housing | 1 | 2016 | 37 | 0.130 |
Why?
|
| Focus Groups | 1 | 2016 | 143 | 0.130 |
Why?
|
| Cerebrosides | 1 | 1996 | 1 | 0.130 |
Why?
|
| Galactosylceramides | 1 | 1996 | 1 | 0.130 |
Why?
|
| Calcium | 1 | 1996 | 30 | 0.120 |
Why?
|
| Data Collection | 1 | 2016 | 238 | 0.120 |
Why?
|
| Health Status Disparities | 1 | 2017 | 149 | 0.120 |
Why?
|
| Retrospective Studies | 2 | 2019 | 2415 | 0.120 |
Why?
|
| Stress, Psychological | 1 | 2017 | 134 | 0.120 |
Why?
|
| Social Support | 1 | 2016 | 207 | 0.110 |
Why?
|
| Reflex, Startle | 1 | 2014 | 1 | 0.110 |
Why?
|
| Psychotherapy, Brief | 1 | 2014 | 19 | 0.110 |
Why?
|
| Emotions | 1 | 2014 | 34 | 0.110 |
Why?
|
| Homosexuality, Female | 1 | 2014 | 7 | 0.110 |
Why?
|
| Cultural Competency | 1 | 2014 | 12 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2018 | 452 | 0.110 |
Why?
|
| Pregnancy Complications | 1 | 2017 | 197 | 0.110 |
Why?
|
| Bisexuality | 1 | 2014 | 11 | 0.110 |
Why?
|
| Amino Acid Sequence | 2 | 2006 | 10 | 0.110 |
Why?
|
| Patient-Centered Care | 2 | 2013 | 186 | 0.110 |
Why?
|
| Molecular Sequence Data | 2 | 2006 | 17 | 0.110 |
Why?
|
| Residence Characteristics | 1 | 2016 | 253 | 0.110 |
Why?
|
| Social Work | 1 | 2014 | 14 | 0.110 |
Why?
|
| Health Maintenance Organizations | 1 | 2016 | 407 | 0.110 |
Why?
|
| Homosexuality, Male | 1 | 2014 | 38 | 0.110 |
Why?
|
| Secondary Prevention | 1 | 2014 | 48 | 0.110 |
Why?
|
| Transgender Persons | 1 | 2014 | 33 | 0.110 |
Why?
|
| Psychotic Disorders | 1 | 2014 | 49 | 0.110 |
Why?
|
| Lipids | 2 | 2006 | 69 | 0.100 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 1925 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2014 | 157 | 0.100 |
Why?
|
| Outcome and Process Assessment (Health Care) | 1 | 2013 | 97 | 0.100 |
Why?
|
| Mass Screening | 2 | 2016 | 672 | 0.100 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 271 | 0.090 |
Why?
|
| Communication | 1 | 2013 | 178 | 0.090 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 1282 | 0.090 |
Why?
|
| Self Report | 3 | 2021 | 257 | 0.090 |
Why?
|
| Cohort Studies | 4 | 2019 | 2514 | 0.090 |
Why?
|
| Patient Readmission | 1 | 2013 | 161 | 0.090 |
Why?
|
| Cattle | 2 | 2000 | 9 | 0.080 |
Why?
|
| Time Perception | 1 | 2008 | 2 | 0.070 |
Why?
|
| Concept Formation | 1 | 2008 | 3 | 0.070 |
Why?
|
| Schizophrenic Psychology | 1 | 2008 | 5 | 0.070 |
Why?
|
| Neoplasms | 1 | 2013 | 446 | 0.070 |
Why?
|
| Heart Failure | 1 | 2013 | 401 | 0.070 |
Why?
|
| Diabetes Complications | 2 | 2018 | 105 | 0.070 |
Why?
|
| Polyelectrolytes | 1 | 2006 | 1 | 0.060 |
Why?
|
| Cytoskeletal Proteins | 1 | 2006 | 1 | 0.060 |
Why?
|
| Protein Isoforms | 1 | 2006 | 1 | 0.060 |
Why?
|
| Polymers | 1 | 2006 | 5 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2006 | 5 | 0.060 |
Why?
|
| Young Adult | 3 | 2019 | 2465 | 0.060 |
Why?
|
| Models, Biological | 1 | 2006 | 28 | 0.060 |
Why?
|
| Mice | 1 | 2006 | 80 | 0.060 |
Why?
|
| Health Services Research | 2 | 2019 | 202 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2022 | 1226 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2020 | 1160 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 969 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 701 | 0.050 |
Why?
|
| Spin Labels | 2 | 2001 | 2 | 0.050 |
Why?
|
| Self Care | 2 | 2014 | 144 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2022 | 37 | 0.050 |
Why?
|
| Safety | 1 | 2022 | 43 | 0.050 |
Why?
|
| Machine Learning | 1 | 2022 | 53 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2022 | 211 | 0.050 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2001 | 1 | 0.040 |
Why?
|
| Permeability | 1 | 2001 | 1 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2001 | 2 | 0.040 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2019 | 535 | 0.040 |
Why?
|
| Azirines | 1 | 2000 | 1 | 0.040 |
Why?
|
| Buffers | 1 | 2000 | 1 | 0.040 |
Why?
|
| Rabbits | 1 | 2000 | 6 | 0.040 |
Why?
|
| Counseling | 1 | 2022 | 174 | 0.040 |
Why?
|
| Prognosis | 2 | 2013 | 603 | 0.040 |
Why?
|
| Grief | 1 | 2020 | 3 | 0.040 |
Why?
|
| Remission Induction | 1 | 2020 | 26 | 0.040 |
Why?
|
| Bereavement | 1 | 2020 | 5 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2020 | 40 | 0.040 |
Why?
|
| Outpatients | 1 | 2021 | 101 | 0.040 |
Why?
|
| Mental Health | 1 | 2021 | 169 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2022 | 805 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2022 | 384 | 0.040 |
Why?
|
| Neoplasms, Second Primary | 1 | 2018 | 31 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2018 | 202 | 0.040 |
Why?
|
| Cytosine | 1 | 1997 | 2 | 0.030 |
Why?
|
| Acyclovir | 1 | 1997 | 5 | 0.030 |
Why?
|
| Organophosphorus Compounds | 1 | 1997 | 2 | 0.030 |
Why?
|
| Organophosphonates | 1 | 1997 | 7 | 0.030 |
Why?
|
| Herpes Simplex | 1 | 1997 | 7 | 0.030 |
Why?
|
| Critical Care | 1 | 2018 | 66 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 1280 | 0.030 |
Why?
|
| Electrochemistry | 1 | 1997 | 1 | 0.030 |
Why?
|
| Intracellular Membranes | 1 | 1997 | 1 | 0.030 |
Why?
|
| Spectrophotometry, Atomic | 1 | 1997 | 1 | 0.030 |
Why?
|
| Isomerism | 1 | 1997 | 2 | 0.030 |
Why?
|
| Liposomes | 1 | 1997 | 2 | 0.030 |
Why?
|
| Potassium | 1 | 1997 | 14 | 0.030 |
Why?
|
| Oxazoles | 1 | 1997 | 1 | 0.030 |
Why?
|
| Polyethylene Terephthalates | 1 | 1997 | 1 | 0.030 |
Why?
|
| Polytetrafluoroethylene | 1 | 1997 | 1 | 0.030 |
Why?
|
| Receptors, Thromboxane | 1 | 1997 | 1 | 0.030 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 1997 | 1 | 0.030 |
Why?
|
| Blood Vessel Prosthesis | 1 | 1997 | 2 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1997 | 63 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2018 | 173 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 1997 | 24 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 1997 | 99 | 0.030 |
Why?
|
| Quality of Life | 1 | 2020 | 499 | 0.030 |
Why?
|
| Models, Organizational | 1 | 2016 | 54 | 0.030 |
Why?
|
| Aspirin | 1 | 1997 | 63 | 0.030 |
Why?
|
| Registries | 1 | 2018 | 460 | 0.030 |
Why?
|
| Methanol | 1 | 1996 | 1 | 0.030 |
Why?
|
| Psychosine | 1 | 1996 | 1 | 0.030 |
Why?
|
| Indicators and Reagents | 1 | 1996 | 5 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 1996 | 5 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1996 | 7 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2016 | 71 | 0.030 |
Why?
|
| Health Personnel | 1 | 2017 | 126 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2016 | 104 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2016 | 188 | 0.030 |
Why?
|
| Thinking | 1 | 2014 | 4 | 0.030 |
Why?
|
| Propensity Score | 1 | 2014 | 76 | 0.030 |
Why?
|
| Recurrence | 1 | 2014 | 165 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2014 | 65 | 0.030 |
Why?
|
| Patient Participation | 1 | 2014 | 119 | 0.030 |
Why?
|
| Hospitals, Community | 1 | 2013 | 22 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 24 | 0.020 |
Why?
|
| Professional-Family Relations | 1 | 2013 | 48 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2014 | 197 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2018 | 622 | 0.020 |
Why?
|
| Family | 1 | 2013 | 106 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 259 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2014 | 397 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2013 | 163 | 0.020 |
Why?
|
| Pregnancy | 1 | 2017 | 1463 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 123 | 0.020 |
Why?
|
| Health Status | 1 | 2013 | 293 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2013 | 277 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 605 | 0.020 |
Why?
|
| Time Factors | 1 | 2013 | 1039 | 0.020 |
Why?
|
| Age Factors | 1 | 2011 | 878 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2013 | 1076 | 0.020 |
Why?
|
| Mental Recall | 1 | 2008 | 29 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2008 | 67 | 0.020 |
Why?
|
| Vero Cells | 1 | 1997 | 1 | 0.010 |
Why?
|
| Foscarnet | 1 | 1997 | 1 | 0.010 |
Why?
|
| Simplexvirus | 1 | 1997 | 2 | 0.010 |
Why?
|
| Gels | 1 | 1997 | 2 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 1997 | 10 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1997 | 4 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 1997 | 2 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1997 | 14 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1997 | 142 | 0.010 |
Why?
|
| Graft Occlusion, Vascular | 1 | 1997 | 1 | 0.010 |
Why?
|
| Swine | 1 | 1997 | 5 | 0.010 |
Why?
|
| Carotid Arteries | 1 | 1997 | 8 | 0.010 |
Why?
|
| Tunica Intima | 1 | 1997 | 10 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1997 | 120 | 0.010 |
Why?
|
| Phosphatidic Acids | 1 | 1989 | 1 | 0.000 |
Why?
|
| Phosphatidylglycerols | 1 | 1989 | 1 | 0.000 |
Why?
|
| Protein Conformation | 1 | 1989 | 2 | 0.000 |
Why?
|
| Glycosylation | 1 | 1989 | 2 | 0.000 |
Why?
|
| In Vitro Techniques | 1 | 1989 | 5 | 0.000 |
Why?
|
Concepts
(243)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(23)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->